As a key pathway of angiogenesis, the ErbB signaling pathway has been implicated in the development of NSCLC patients with BMs as evidenced by overexpression and higher activity than in corresponding primary tumors [35]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.